Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Consensus "Moderate Buy": Eleven analysts cover Sutro Biopharma with a consensus rating of Moderate Buy (2 sell, 1 hold, 7 buy, 1 strong buy) and an average 1-year target of $37.3750.
• Notable analyst moves include Deutsche Bank raising its target to $55 and Wells Fargo upgrading to overweight with a $27 target, while Citigroup upgraded to outperform and Weiss Ratings remains bearish.
• Institutional investors own about 96.99% of the stock; shares traded at $25.86 (down 3.4%), market cap ~$428.5M, 50-day/200-day moving averages of $21.00/$14.10, and a 52-week range of $5.23–$27.92.

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven ratings firms that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $37.3750.

STRO has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Sutro Biopharma from $51.00 to $55.00 and gave the company a "buy" rating in a research report on Wednesday, March 25th. Wells Fargo & Company upgraded shares of Sutro Biopharma from an "equal weight" rating to an "overweight" rating and boosted their target price for the company from $8.00 to $27.00 in a research report on Tuesday, March 24th. Weiss Ratings restated a "sell (d-)" rating on shares of Sutro Biopharma in a research report on Monday, December 22nd. Wall Street Zen upgraded shares of Sutro Biopharma from a "sell" rating to a "hold" rating in a research report on Saturday, March 28th. Finally, Citigroup upgraded shares of Sutro Biopharma to an "outperform" rating in a research report on Tuesday, January 20th.

Hedge Funds Weigh In On Sutro Biopharma

Large investors have recently added to or reduced their stakes in the company. GSA Capital Partners LLP purchased a new position in Sutro Biopharma during the third quarter valued at approximately $152,000. Jacobs Levy Equity Management Inc. purchased a new position in Sutro Biopharma during the third quarter valued at approximately $387,000. Two Sigma Investments LP lifted its holdings in Sutro Biopharma by 244.8% during the third quarter. Two Sigma Investments LP now owns 396,785 shares of the company's stock valued at $345,000 after purchasing an additional 281,717 shares in the last quarter. Shay Capital LLC lifted its holdings in Sutro Biopharma by 20.1% during the third quarter. Shay Capital LLC now owns 312,051 shares of the company's stock valued at $271,000 after purchasing an additional 52,162 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in Sutro Biopharma during the fourth quarter valued at approximately $265,000. Hedge funds and other institutional investors own 96.99% of the company's stock.

Sutro Biopharma Stock Down 3.4%

Shares of STRO stock opened at $25.86 on Friday. The company has a 50 day moving average price of $21.00 and a 200-day moving average price of $14.10. Sutro Biopharma has a 52 week low of $5.23 and a 52 week high of $27.92. The firm has a market capitalization of $428.50 million, a PE ratio of -0.99 and a beta of 1.31.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.